Overview

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate safety, pharmacokinetics, and clinical activity.
Phase:
Phase 1
Details
Lead Sponsor:
Humanigen, Inc.
KaloBios Pharmaceuticals